EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $311,379 | -85.9% | 19,745 | -46.2% | 0.04% | -71.3% |
| Q4 2019 | $2,205,000 | -28.0% | 36,701 | -32.2% | 0.14% | -25.3% |
| Q3 2019 | $3,062,000 | -0.2% | 54,124 | -1.8% | 0.18% | +0.6% |
| Q2 2019 | $3,068,000 | +10.2% | 55,100 | -0.0% | 0.18% | +15.3% |
| Q1 2019 | $2,783,000 | +55.9% | 55,114 | +24.4% | 0.16% | +57.0% |
| Q4 2018 | $1,785,000 | -64.5% | 44,311 | -39.0% | 0.10% | -52.2% |
| Q3 2018 | $5,033,000 | -20.8% | 72,600 | -13.6% | 0.21% | -13.3% |
| Q2 2018 | $6,355,000 | +44.0% | 83,991 | +0.3% | 0.24% | +61.7% |
| Q1 2018 | $4,412,000 | -22.0% | 83,741 | -20.9% | 0.15% | -9.1% |
| Q4 2017 | $5,654,000 | +232.2% | 105,837 | +451.2% | 0.16% | -29.6% |
| Q4 2015 | $1,702,000 | -36.4% | 19,200 | -46.9% | 0.23% | +288.3% |
| Q3 2015 | $2,676,000 | +25.2% | 36,152 | +36.8% | 0.06% | +7.1% |
| Q2 2015 | $2,137,000 | +108.1% | 26,434 | +7.8% | 0.06% | +115.4% |
| Q1 2015 | $1,027,000 | – | 24,527 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |